In vitro study examining the effectiveness of antiseptic prophylaxis for antibiotic-resistant bacterial endophthalmitis

Abstract

Current antisepsis guidelines are insufficient for patients with carriage of antibiotic-resistant organisms on their ocular surface, rendering such patients at increased risk for endophthalmitis with intraocular surgery.

Transcriptomics and systems biology identify non-antibiotic drugs for the treatment of ocular bacterial infection

“…DC and CT, on the other hand, possess both antibacterial as well as anti-inflammatory properties. MRSA is increasingly being reported in causing ocular infections, including endophthalmitis (O'Rourke et al, 2021). Owing to the growing concern of multidrug resistance (MDR) among MRSA strains (Huz et al, 2017) and treatment failures, we tested the ability of the predicted drugs to reduce the inflammation in response to USA300 infection.…”

Antimicrobials and antiseptics: Lowering effect on ocular surface bacterial flora – A systematic review

“…Regarding concentration and exposure time, PVI 5% for a minimum of 3 min appears to be a regimen widely reported as effective (Barry et al, 2013; Cao et al, 2013; Huang et al, 2016). This protocol, however, is not sufficient to completely eradicate MDR organisms in vitro (O'Rourke et al, 2021). In general, more diluted PVI formulations, namely from 0.1% to 1%, are characterized by a rapid (within 15 s) but short bactericidal effect requiring repeated applications, whereas PVI from 2.5% to 10% showed a delayed onset of bactericidal activity (from 30 to 120 s) with longer duration of bactericidal effect (Berkelman et al, 1982).…”

“…Conversely, Inagaki et al (2013) documented no difference in the reduction of CBL achieved with PVI 5% vs. CLX 0.02%. Finally, PVI 5% for 3 min may be more effective in the eradication of MRSA and MR S. epidermidis compared with CLX 0.05% for the same contact time (O'Rourke et al, 2021).…”